DEXA Body Composition: Sex and Menstrual Cycle Differences Explained

Why Sex Hormones Change What DEXA Measures

DEXA does not measure one static tissue. It partitions body mass into three compartments: fat mass, lean soft tissue (primarily muscle plus water), and bone mineral content. Sex hormones regulate the size and distribution of all three compartments throughout life and within each menstrual cycle. Ignoring these hormonal influences produces misinterpreted serial scans, especially for patients on GLP-1 agonists or hormone therapy where the clinical question is whether lean mass is being preserved.

Estrogen and Fat Distribution

Estrogen promotes adipogenesis in subcutaneous depots at the gluteal and femoral regions while suppressing visceral fat accumulation [1]. Women in their reproductive years carry roughly 6 to 11 percentage points more total body fat than age-matched men [2], and most of that excess sits in subcutaneous rather than visceral compartments. DEXA captures this as a lower android-to-gynoid fat ratio in premenopausal women compared with men or postmenopausal women.

After menopause, estrogen withdrawal shifts adipose tissue centrally. A longitudinal analysis published in the Journal of Clinical Endocrinology and Metabolism found a 49% increase in visceral adipose tissue area in the six years following the final menstrual period, independent of total weight change [3]. That shift appears on DEXA as a rising android-to-gynoid ratio and rising visceral fat mass even when the scale does not move.

Testosterone and Lean Mass

Testosterone stimulates muscle protein synthesis through androgen-receptor-mediated upregulation of IGF-1 and mTOR signaling [4]. Men average 10 to 15 kg more appendicular lean mass than women of similar height and age [5]. Each 1 SD increase in free testosterone in community-dwelling men associates with approximately 2 to 3 kg greater appendicular lean mass on DEXA, based on data from the Framingham Heart Study offspring cohort [6].

In women, even the modest free testosterone present in normal physiology contributes to lean mass maintenance. Androgen-deficient women (e.g., after bilateral oophorectomy without testosterone replacement) show accelerated lean mass loss that DEXA detects within 12 months of surgery [7].

Progesterone, Fluid, and Scan Timing

Progesterone is the most acutely new hormone for serial DEXA interpretation. In the luteal phase (days 15 to 28), progesterone peaks and promotes sodium and water retention via aldosterone cross-reactivity [8]. Total body water can increase by 0.5 to 2.0 L, which DEXA software misattributes partially to lean soft tissue and partially to fat mass because neither compartment is pure tissue.

A controlled study in Medicine and Science in Sports and Exercise (N=59 premenopausal women) measured DEXA across four menstrual cycle phases and found fat-mass readings varied by a mean of 1.1 kg (range 0.4 to 1.8 kg) across phases, with the highest readings in the mid-luteal phase and the lowest in the early follicular phase [9]. That 1.1 kg swing exceeds the minimum detectable change for most clinical DEXA protocols.

Clinical implication: always schedule serial DEXA scans for women in days 1 to 7 of the menstrual cycle (early follicular phase) to minimize luteal-phase fluid artifact.

Normal and Optimal DEXA Body Composition Ranges

"Normal" and "optimal" are not identical targets. Normal ranges reflect population distributions; optimal ranges reflect the body composition associated with the lowest risk of metabolic disease, functional decline, and all-cause mortality.

Body Fat Percentage by Sex and Age

The American College of Sports Medicine (ACSM) and the National Institutes of Health publish age-stratified reference ranges [10]. The table below summarizes ACSM fitness-category thresholds:

| Age Group | Men: Optimal (Fitness) | Men: Acceptable | Women: Optimal (Fitness) | Women: Acceptable | |---|---|---|---|---| | 20 to 39 | 8 to 19% | 20 to 24% | 21 to 33% | 34 to 38% | | 40 to 59 | 11 to 21% | 22 to 27% | 23 to 35% | 36 to 40% | | 60 to 79 | 13 to 24% | 25 to 29% | 24 to 36% | 37 to 41% |

These ranges come from NHANES-derived DEXA reference data and are sex-specific because the female reproductive system requires a minimum essential fat fraction of approximately 10 to 13% for hormonal function [11].

Visceral Adipose Tissue Thresholds

Visceral adipose tissue (VAT) area measured by DEXA or CT carries stronger cardiometabolic predictive value than total body fat percentage. The International Diabetes Federation and most metabolic syndrome guidelines use a VAT area threshold of 100 cm² as a risk cut-point [12]. Above 160 cm², insulin resistance is nearly universal in cross-sectional data from the NHANES body composition subsample [13].

Women consistently show lower VAT than men at equivalent BMI in reproductive years, but that advantage erodes after menopause. By age 65, VAT areas in women and men converge within 10 to 15% [3].

Appendicular Lean Mass Index

Sarcopenia diagnosis uses DEXA-derived appendicular lean mass index (ALMI): appendicular lean mass in kg divided by height in meters squared. The Foundation for the National Institutes of Health (FNIH) Sarcopenia Project set the following low-lean-mass thresholds based on outcome data from nine cohort studies (N=26,625) [14]:

• Men: ALMI <0.789 (i.e., <0.789 × height² kg)
• Women: ALMI <0.512

Using absolute cut-points rather than percentage thresholds matters because tall individuals otherwise appear falsely lean.

How GLP-1 Agonists Interact with Sex-Specific Body Composition

GLP-1 receptor agonists are now among the most common reasons clinicians order serial DEXA scans, and sex-hormone context is essential for interpreting those results.

STEP-1 Trial: What DEXA Showed

In STEP-1 (N=1,961), semaglutide 2.4 mg subcutaneous weekly produced a mean 14.9% total body weight loss at 68 weeks versus 2.4% with placebo [15]. A DEXA substudy found that 87.8% of weight lost was fat mass and 12.2% was lean mass, a ratio broadly consistent across sexes in that analysis [16]. The lean-mass loss fraction with GLP-1 therapy is clinically meaningful: a 15 kg weight loss would mean roughly 1.8 kg of lean mass lost, enough to reduce grip strength and six-minute walk distance in older adults.

Sex Differences in GLP-1 Response on DEXA

Women in STEP-1 lost a slightly higher absolute percentage of body fat (approximately 1.2 percentage points more than men), consistent with women starting with higher baseline fat mass [15]. Men showed greater absolute lean mass preservation in kilogram terms, likely reflecting higher baseline lean mass and the anabolic influence of testosterone [16].

Postmenopausal women on GLP-1 therapy without concurrent estrogen therapy may show disproportionate lean mass loss compared with premenopausal women, based on mechanistic data showing estrogen's protective role in muscle protein turnover [17]. This is one reason some longevity-medicine clinicians combine GLP-1 therapy with resistance training prescriptions and protein intake targets of 1.6 to 2.2 g/kg/day.

Monitoring Interval on GLP-1 Therapy

A reasonable DEXA monitoring interval during active GLP-1 dose titration is every 6 months. The minimum detectable change for lean mass on most clinical DEXA machines is approximately 0.8 to 1.2 kg, so shorter intervals produce noise-dominated data [18].

HealthRX Clinical Framework for GLP-1 DEXA Monitoring:

1. Baseline DEXA before starting GLP-1 therapy (record ALMI, VAT area, android-to-gynoid ratio).
2. For premenopausal women, schedule the baseline and all follow-up scans in days 1 to 7 of the cycle.
3. Repeat at 6 months and 12 months during active dose titration.
4. Flag any lean-mass loss exceeding 1.5 kg per 6-month interval for dietary protein and resistance-exercise review.
5. If ALMI approaches the FNIH low-lean-mass threshold, consider adding a handgrip-strength and 4-meter gait-speed assessment before attributing all changes to GLP-1 pharmacology.

Hormone Therapy Effects on DEXA Body Composition

Exogenous hormones alter DEXA results in predictable and trackable ways. Understanding those effects allows clinicians to distinguish treatment response from artifact.

Estrogen-Based HRT in Postmenopausal Women

The Women's Health Initiative (WHI) DEXA substudy found that conjugated equine estrogen 0.625 mg/day reduced annual lean mass loss by approximately 0.14 kg/year and slowed VAT accrual by roughly 7% per year in women aged 50 to 79 [19]. Total fat mass did not decrease significantly; estrogen redistributed fat from visceral to subcutaneous depots rather than eliminating it. That redistribution is metabolically favorable because subcutaneous fat is far less inflammatory than VAT.

The Endocrine Society 2022 clinical practice guideline on menopause hormone therapy states: "Estrogen therapy reduces visceral adiposity and preserves lean mass during the menopausal transition, with the magnitude of effect dependent on route, dose, and timing relative to final menstrual period" [20].

Testosterone Therapy in Men (TRT)

The Testosterone Trials (TTrials, N=790 men aged 65+, testosterone <275 ng/dL) showed that testosterone undecanoate gel increased lean mass by a mean 1.6 kg and decreased fat mass by 1.4 kg over 12 months on DEXA, compared with placebo [21]. The lean-mass gain was primarily in the trunk and lower extremities, detectable as increased ALMI.

Serial DEXA at 6 and 12 months is standard practice for men on TRT in most endocrinology programs. The Endocrine Society TRT guideline recommends monitoring lean and fat mass by DEXA at 12 months and every 2 years thereafter once stable [22].

Testosterone Therapy in Women

Low-dose testosterone (typically 0.5 to 2 mg/day transdermal in women) is used off-label for hypoactive sexual desire disorder and androgen deficiency after oophorectomy. DEXA studies in this population show modest lean mass increases of 0.3 to 0.8 kg over 6 months without significant total fat mass change [7]. The androgenic lean-mass signal is smaller in women because doses are intentionally subphysiologic by male standards.

Practical Scan Standardization for Accurate Serial Results

Small methodological errors compound across serial scans and can mimic or mask real body composition change.

Hydration and Food Timing

DEXA lean soft tissue includes total body water. A 1 L difference in hydration status shifts lean mass readings by approximately 0.9 to 1.1 kg [23]. Patients should be scanned in a fasted, euhydrated state (no food or caloric beverages for 3 hours; normal water intake the morning of the scan).

Same Machine, Same Protocol

DEXA scanners from different manufacturers (Hologic vs. GE Lunar) use different algorithms and cannot produce interchangeable absolute values. A cross-calibration study published in the Journal of Clinical Densitometry found mean fat-mass differences of 3.2 to 4.1 percentage points between Hologic Horizon and GE Lunar iDXA for the same subjects [24]. Serial tracking must use the same scanner model, ideally the same physical unit.

Clothing and Positioning

Metal objects, thick clothing, and off-center positioning each introduce millimeter-level bone-map misalignments that propagate into fat and lean mass errors. Standard protocol: light paper gown, no metal, arms at sides with palms facing down, legs in neutral rotation.

Cycle-Phase Documentation

Every DEXA order for a premenopausal woman should include cycle day in the scan record. Without that datum, a 1.1 kg fat-mass increase between a day-20 baseline and a day-3 follow-up scan might be interpreted as fat gain when it reflects only fluid retention [9]. Documenting cycle day costs nothing and eliminates a major source of interpretive error.

DEXA vs. Other Body Composition Methods: Where It Fits

DEXA is not the only body composition tool, and knowing its relative strengths prevents overinterpretation.

DEXA vs. Bioelectrical Impedance Analysis

Bioelectrical impedance analysis (BIA) devices range from consumer scales to clinical eight-electrode devices (e.g., InBody 770). BIA is faster and cheaper but has a reported fat-mass test-retest error of 3 to 5% versus 1 to 3% for DEXA [25]. BIA is also more vulnerable to hydration shifts, making it particularly unreliable across menstrual cycle phases. For GLP-1 lean-mass tracking or hormone-therapy monitoring, DEXA is the preferred method.

DEXA vs. CT and MRI

CT and MRI provide the gold standard for visceral fat quantification (single-slice L4 CT) and muscle cross-sectional area. DEXA estimates VAT by regional subtraction algorithms; those algorithms show correlation coefficients of 0.87 to 0.92 against CT in validation studies [26], which is clinically acceptable but not identical. For research-grade VAT measurement, CT remains superior. For routine clinical monitoring with repeated exposures considered, DEXA's radiation dose of 1 to 10 µSv makes it substantially preferable to CT (200 to 1,000 µSv per abdominal CT).

Key Numbers to Bring to Your Clinician

A single DEXA scan produces a long printout. These are the values with the strongest clinical evidence behind them:

• Total body fat percentage: compare to age- and sex-matched ACSM reference ranges [10].
• ALMI (appendicular lean mass index): compare to FNIH thresholds (<0.789 for men, <0.512 for women) [14].
• VAT area (cm²): target <100 cm²; values above 160 cm² associate with near-universal insulin resistance [13].
• Android-to-gynoid fat ratio: rising ratio in women signals estrogen-withdrawal fat redistribution [3].
• Lean mass change from prior scan: a loss exceeding 1.5 kg per 6-month interval on GLP-1 therapy warrants dietary and exercise review.

The Endocrine Society's position statement on body composition assessment states: "DEXA provides clinically actionable compartmental data that BMI and waist circumference alone cannot supply, particularly for monitoring pharmacological interventions affecting fat and lean mass simultaneously" [27].